Dachaigh › Ailseachadh an Ae (Carcinoma Hepatocellular) › Pennsylvania › Pittsburgh
Sgrùdaidhean clionaigeach Ailseachadh an Ae (Carcinoma Hepatocellular) ann an Pittsburgh, PA
Tha 15 sgrùdaidhean airson Ailseachadh an Ae (Carcinoma Hepatocellular) a’ lorg phàirtichean aig làraichean ann agus timcheall air Pittsburgh (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
A’ fastadhÌre 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
A’ fastadhÌre 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
A’ fastadhÌre 3
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A’ fastadhÌre 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
A’ fastadhSgrùdadh amharc
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
A’ fastadhÌre 2
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
A’ fastadhÌre 1
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
A’ fastadhÌre 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
A’ fastadhÌre 2
- UPMC Hillman Cancer Center, Pittsburgh
Sgrùdaidhean Ailseachadh an Ae (Carcinoma Hepatocellular) ann am bailtean eile
- Houston, TX31 sgrùdaidhean
- New York City, NY24 sgrùdaidhean
- Dallas, TX19 sgrùdaidhean
- Los Angeles, CA19 sgrùdaidhean
- Boston, MA18 sgrùdaidhean
- Cleveland, OH18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Philadelphia, PA16 sgrùdaidhean
- San Francisco, CA14 sgrùdaidhean
- Orange, CA14 sgrùdaidhean
- Jacksonville, FL14 sgrùdaidhean
- San Antonio, TX13 sgrùdaidhean
Sgrùdaidhean eile ann an Pittsburgh
- Aillse Sgamhain Neo-chealla-beag48 sgrùdaidhean
- Aillse (gach seòrsa)41 sgrùdaidhean
- Aillse a' bhroilleach39 sgrùdaidhean
- Aillse colorectal32 sgrùdaidhean
- Ailse metastatach31 sgrùdaidhean
- Melanoma31 sgrùdaidhean
- Cancer Ovarian30 sgrùdaidhean
- Ailse Endometrial23 sgrùdaidhean
- Aillse Prostata23 sgrùdaidhean
- Ailseachadh nan Sgamhan23 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil22 sgrùdaidhean
- Buailteach22 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.